Mitsubishi Tanabe Sees Open Road With Telaprevir Approval And Merck's Boceprevir Discontinued In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Mitsubishi Tanabe Pharma Corp. received a double dose of good news Sept. 26, leading a list of drugs that received marketing approval from Japan's Ministry of Health, Labor and Welfare with in-licensed protease inhibitor telaprevir and oral multiple sclerosis therapy fingolimod